glp-1 adoption Impact: How GLP-1s Are Changing the Diabetes Treatment Paradigm How Weight Loss Drugs Are

[17] [18] This is a recognised caution for GLP-1 receptor agonist therapies (see semaglutide and tirzepatide UK SmPCs) and is likely relevant to retatrutide

[57] demonstrated that GLP-1 based agents were associated with a three-fold increased risk of pancreatic enzyme elevation relative to controls, yet did not indicate a significant rise in pancreatitis or pancreatic cancer

World Health Organization

Months 1224: Consolidation of results and habit-building for long-term maintenance

63% of participants on the 15mg dose achieved at least 20% weight loss, compared to 1.3% on placebo

Eating slowly allows the brain more time to register the enhanced fullness signals sent due to the medication